By: IPP Bureau
Last updated : May 19, 2026 5:34 pm
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
HAB Pharmaceuticals and Signature Phytochemical Industries have completed a strategic merger through a slump sale, bringing both businesses under a single consolidated entity with an estimated turnover of approximately Rs. 600 crore after adjusting for intercompany sales.
The transaction was finalized in March 2026 and is aimed at streamlining operations, harmonizing corporate systems, and strengthening governance to drive future growth and operational efficiency.
The merger significantly expands the combined entity’s manufacturing, research, and development capabilities, with a strategic focus on specialty drugs for oncology, autoimmune disorders, chronic illnesses, and rare diseases. The company is also accelerating its international expansion strategy, targeting high-growth markets across Latin America, Central Asia, and Southeast Asia.
As part of its expansion roadmap, HAB Pharmaceuticals is commissioning two new manufacturing facilities. The first is a sterile manufacturing plant dedicated to semaglutide products, prefilled syringes, injectables, vials, and lyophilized formulations, while the second is a fully automated closed-loop oral solid dosage (OSD) facility. Both plants are expected to commence commercial production by August 2026.
“This merger marks a pivotal moment for our company,” said Saurabh Agarwal, Director, HAB Pharma. “By consolidating our operations with Signature and strengthening our manufacturing capacities, we are now positioned for substantial growth. Our focus on innovation, niche products, and increasing our export and R&D capabilities will solidify the company’s position in the pharmaceutical industry.”
Urvee Garg, Director, HAB Pharma said, “This merger represents the next chapter in HAB Pharma’s growth story. We are focused on creating a more cohesive organization that can better serve both our domestic and international markets. With a solid foundation in manufacturing, a commitment to quality, and a focus on affordability, we are confident that HAB Pharma will continue to thrive and deliver innovative healthcare solutions across the world.”
Looking ahead, HAB Pharma aims to scale its revenues to Rs. 2,500–3,000 crore by 2030 through expanded manufacturing infrastructure, enhanced R&D capabilities, and a strategic focus on off-patent molecules and complex dosage forms. T